Skip to main content
. 2019 May 1;11(1):e2019025. doi: 10.4084/MJHID.2019.025

Figure 2.

Figure 2

Proportion (%) of patients in Italy (left hand panel) and the rest of the European SIMPLICITY population (excluding Italy; right hand panel) who discontinued TKI treatment within the first 12 months of first-line TKI. DAS: dasatinib; IM: imatinib; NIL: nilotinib; TKI: tyrosine kinase inhibitor.